温肾方对超高alt水平20uln≤alt≤30ulnhbeag阳性慢性乙型肝炎患者临床疗效评价-clinical evaluation of wenshen recipe on chronic hepatitis b patients with ultra-high alt level of 20 uln ≤ alt ≤ 30 ulnhbeag.docxVIP

下载本文档

9
0
约6.68万字
约 80页
2018-09-08 发布于上海
举报
版权申诉

温肾方对超高alt水平20uln≤alt≤30ulnhbeag阳性慢性乙型肝炎患者临床疗效评价-clinical evaluation of wenshen recipe on chronic hepatitis b patients with ultra-high alt level of 20 uln ≤ alt ≤ 30 ulnhbeag.docx

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

温肾方对超高alt水平20uln≤alt≤30ulnhbeag阳性慢性乙型肝炎患者临床疗效评价-clinical evaluation of wenshen recipe on chronic hepatitis b patients with ultra-high alt level of 20 uln ≤ alt ≤ 30 ulnhbeag

成都中医药大学硕士学位论文成都中医药大学硕士学位论文万方数据万方数据水平(20ULN≤ALT≤30ULN)HBeAg 阳性慢性乙型肝炎有效、安全。关键词：温肾方替比夫定超高 ALT 水平慢性乙型肝炎疗效 2 Abstract Purpose：Observe curative effect of Wenshen decoction for the ultra-high ALT (20ULN≤ALT≤30ULN)HBeAg positive Patients with chronic hepatitis B. Methods: To use a prospective study design of the RCT for clinical scheme design. 60 patients were devided into two groups randomly,（29 of them were in treatment group ,31of them were in control group） .ALL of them were given telbivudine、 reduced glutathione Polyene phosphatidylcholine when they were in hospital,moreover,the treatment group were also given Wenshen decoction. Set ALT ≤ 2ULN and patients condition allowed as the discharge stangdard. After discharged from hospital，both of the two groups were given telbivudine, the treatment group were also given Wenshen decoction. All of the two groups’course of treatment were 52 weeks.To observe The number of days of hospitalization，TCM syndrome score, Curative effect ， the MOS item short from health survey score, biochemical responses,virological response,HBeAg serological response, Fibroscan elastic value improvement, Serum CK, adverse reactions. Results: Clinical curative effect：The total effective rate of treatment group was higher than control group (PO.O5). TCM syndrome score: After treatment, compared with control group, the TCM syndrome score decreased more significantly. (P0.05). SF-36 scale scores: Compared with control group, The factors points to improve are more obvious in the treatment group (P0.05). Two groups of hospital stay (days): the average hospital stay of the treatment and control group were 15.7+4.4,20.8+5.6,respectively; the hospital stay in the treatment group was significantly shorter than that in the control group (P0.05). Biochemical responses: The recovery rate of ALT of treatment group was significantly higher than that of control group (P0.05). 3 Virological response：In treatment group, the negative rate of HBV